UCBJY Quote, Financials, Valuation and Earnings

Celyad Oncology SA has a net margin of -- compared to UCB SA's net margin of --. UCB SA's return on equity of 13.88% beat Celyad Oncology SA's return on equity of --.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Celyad Oncology SA has an analysts' consensus of -- which suggests that it could fall by --. Given that UCB SA has higher upside potential than Celyad Oncology SA, analysts believe UCB SA is more attractive than Celyad Oncology SA.

UCB SA has a beta of 0.678, which suggesting that the stock is 32.194% less volatile than S&P 500. In comparison Celyad Oncology SA has a beta of 0.181, suggesting its less volatile than the S&P 500 by 81.876%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.49%. Celyad Oncology SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 15.96% of its earnings as a dividend. Celyad Oncology SA pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Celyad Oncology SA quarterly revenues of --. UCB SA's net income of -- is lower than Celyad Oncology SA's net income of --. Notably, UCB SA's price-to-earnings ratio is 37.32x while Celyad Oncology SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 8.52x versus 30.84x for Celyad Oncology SA. Usually stocks with elevated PS ratios are considered overvalued.

Galapagos NV has a net margin of -- compared to UCB SA's net margin of -286.67%. UCB SA's return on equity of 13.88% beat Galapagos NV's return on equity of -16.48%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Galapagos NV has an analysts' consensus of $27.34 which suggests that it could fall by -18.17%. Given that Galapagos NV has higher upside potential than UCB SA, analysts believe Galapagos NV is more attractive than UCB SA.

UCB SA has a beta of 0.678, which suggesting that the stock is 32.194% less volatile than S&P 500. In comparison Galapagos NV has a beta of 0.236, suggesting its less volatile than the S&P 500 by 76.408%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.49%. Galapagos NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. UCB SA pays 15.96% of its earnings as a dividend. Galapagos NV pays out -- of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Galapagos NV quarterly revenues of $83.2M. UCB SA's net income of -- is lower than Galapagos NV's net income of -$238.4M. Notably, UCB SA's price-to-earnings ratio is 37.32x while Galapagos NV's PE ratio is 21.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 8.52x versus 7.03x for Galapagos NV. Usually stocks with elevated PS ratios are considered overvalued.

Ion Beam Applications SA has a net margin of -- compared to UCB SA's net margin of --. UCB SA's return on equity of 13.88% beat Ion Beam Applications SA's return on equity of 8.22%.

UCB SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Ion Beam Applications SA has an analysts' consensus of -- which suggests that it could fall by --. Given that UCB SA has higher upside potential than Ion Beam Applications SA, analysts believe UCB SA is more attractive than Ion Beam Applications SA.

UCB SA has a beta of 0.678, which suggesting that the stock is 32.194% less volatile than S&P 500. In comparison Ion Beam Applications SA has a beta of 1.153, suggesting its more volatile than the S&P 500 by 15.339%.

UCB SA has a quarterly dividend of $0.79 per share corresponding to a yield of 0.49%. Ion Beam Applications SA offers a yield of 1.52% to investors and pays a quarterly dividend of $0.28 per share. UCB SA pays 15.96% of its earnings as a dividend. Ion Beam Applications SA pays out 53.12% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

UCB SA quarterly revenues are --, which are smaller than Ion Beam Applications SA quarterly revenues of --. UCB SA's net income of -- is lower than Ion Beam Applications SA's net income of --. Notably, UCB SA's price-to-earnings ratio is 37.32x while Ion Beam Applications SA's PE ratio is 24.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for UCB SA is 8.52x versus 0.82x for Ion Beam Applications SA. Usually stocks with elevated PS ratios are considered overvalued.